Biotest AG (Biotest AG) EBIT per Share : $6.33 (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biotest AG EBIT per Share?

Biotest AG's EBIT per Share for the three months ended in Mar. 2024 was $1.49. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $6.33.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Biotest AG's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Biotest AG was 198.40% per year. The lowest was -59.30% per year. And the median was -4.30% per year.

BIESF's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Biotest AG's EBIT for the three months ended in Mar. 2024 was $59.3 Mil.

Biotest AG EBIT per Share Historical Data

The historical data trend for Biotest AG's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biotest AG EBIT per Share Chart

Biotest AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.26

-0.49

-1.41

-0.30

4.03

Biotest AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.15	0.87	3.64	0.34	1.49

Biotest AG EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Biotest AG's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	159.542	/	39.571
=	4.03

Biotest AG's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	59.348	/	39.865
=	1.49

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.33

Biotest AG (OTCPK:BIESF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Biotest AG EBIT per Share Related Terms

Thank you for viewing the detailed overview of Biotest AG's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotest AG (Biotest AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biotest AG (OTCPK:BIESF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

BIO3:Germany BIO3:Austria

Address

Landsteinerstrasse 5, Dreieich, DEU, 63303

Website

https://www.biotest.com

Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The operating business segments are Therapy, Plasma and Services, and Other segments. It generates maximum revenue from the Therapy segment. Geographically, it derives a majority of revenue from Central Europe and also has a presence in other countries.